Compare Novartis AG (NVS) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Sezzle Inc — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while Sezzle Inc trades at $128.64 (market cap $3.95B). The key difference: Novartis AG is far larger — about 68× Sezzle Inc's market cap, and Novartis AG pays a 3.31% dividend while Sezzle Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Sezzle Inc for 15 Days on average.
| NVS | SEZL | |
|---|---|---|
Market Cap | $268.57B | $3.95B |
Volume | 1,532,573 | 550,075 |
Sector | Health | Financials |
52-Week High | $168.62 | $188.55 |
52-Week Low | $121.80 | $50.97 |
Typical Hold Time | 82 Days | 15 Days |
Enterprise Value | $309.89B | $3.99B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, down 0.12% with a bearish technical signal. The stock shows strong fundamentals with 24.67% net margin and $14B net income, though recent earnings were mixed with a Q1 miss. Analyst consensus is cautious with 68% hold ratings and a $146 target. Recent $7.8B licensing deal with China's Abogen highlights strategic moves amid pipeline setbacks.
Outlook remains balanced: valuation metrics appear reasonable (P/E 21.6) and profitability is robust, but clinical trial failures and investor scrutiny over M&A strategy pose risks. The stock trades near consensus target with institutional sentiment leaning neutral amid ongoing pipeline execution challenges.
SEZL trades at $117.22, up 2.96% today, showing strong momentum with bullish technical indicators and trading above key support levels. The company demonstrates exceptional financial performance with 51.7% revenue growth in Q2 2026, 30.35% net income margin, and 88.85% ROE. Recent product launches including Sezzle Send and SezzleCash are driving user acquisition and platform growth.
SEZL presents a compelling growth opportunity with analyst consensus price target of $168 representing 43% upside potential. Key risks include competitive BNPL market pressures and potential credit quality concerns. The stock's premium valuation (P/E 25.71) is supported by strong earnings growth and profitability metrics, though investors should monitor execution of expansion initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
